Search

Displaying results 2201 - 2210 of 7479 in total
  1. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). … According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments

  2. Drug

    Zopapogene imadenovec

    go.drugbank.com/drugs/DB24672
    ApprovedInvestigational

    [L54081] Zopapogene imadenovec is a non-replicating adenoviral vector–based immunotherapy that expresses a fusion antigen from selected regions of HPV-6/11 proteins to elicit an immune response in RRP.

  3. Drug

    Suprofen

    go.drugbank.com/drugs/DB00870
    ApprovedWithdrawn

    An ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.

  4. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate. … [A261690] Oxalate, particularly calcium oxalate, precipitation is the main cause of kidney stones formation; therefore, blocking the production of oxalate can help alleviate renal symptoms.

  5. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026] … [A225985, A225990, A225995] Faricimab is an IgG<sub>1</sub>-derived bispecific antibody capable of simultaneously binding to and depleting VEGF-A and Ang-2, which has been developed to improve therapeutic

  6. Drug

    Prenylamine

    go.drugbank.com/drugs/DB04825
    ApprovedWithdrawn

    Prenylamine was withdrawn from the Canadian, US, and UK markets in 1988 due to concerns regarding cardiac arrhythmias.

    Synonyms: DL-prenylamine
  7. Drug

    Futibatinib

    go.drugbank.com/drugs/DB15149
    ApprovedInvestigational

    Futibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and

    Synonyms: 1-((3S)-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3, 4-d) pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one, 1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one
  8. Drug

    Benzoctamine

    go.drugbank.com/drugs/DB09021
    Experimental

    It can also be used as an anxiolytic with the same efficacy as chlordiazepoxide for treating anxiety neurosis. … It can be used as a sedative which does not depress the respiratory system, but rather stimulates it.

  9. Drug

    Sevabertinib

    go.drugbank.com/drugs/DB21667
    ApprovedInvestigational

    Sevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Sevaber...

  10. Drug

    Tetrachlorodecaoxide

    go.drugbank.com/drugs/DB05389
    Approved

    The Corporation has commenced a Phase II clinical trial in an effort to demonstrate the efficacy of WF10 in combination with Xeloda (capecitabine) in the treatment of pancreatic cancer.